Obesity drugmaker Novo Nordisk's Q1 profit beats forecast

Catalent

02/05/2024 06:32

LONDON, May 2 (Reuters) - Novo Nordisk  NOVOb.CO  posted
on Thursday first-quarter operating profit above analyst
forecasts, as the Danish drugmaker races to boost output of its
hugely popular weight-loss drug Wegovy and fend off competition
from Eli Lilly.

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Novo Nordisk expects double-digit growth as it boosts Wegovy
supplies    L1N3EL0YM
EARNINGS POLL - Novo Nordisk A/S first quarter results due on
May 2    L8N3H31LN
FACTBOX-Launches and prices of Novo Nordisk's weight-loss drug
Wegovy    L8N3CO3HE
Eli Lilly lifts profit view on diabetes and weight-loss drug
strength    L4N3H33BI
Novo Nordisk's parent to buy Catalent for $16.5 bln to boost
Wegovy supply    L4N3EQ2PL
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Reporting by Maggie Fick
Editing by Terje Solsvik)
 ((maggie.fick@thomsonreuters.com; +44 7890 916706;))